SF
TSHA icon

Summit Financial’s Taysha Gene Therapies TSHA Stock Holding History

Summit Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.1K Sell
10,888
-260
-2% -$1.54K ﹤0.01% 1567
2026
Q1 		$49.8K Buy
+11,148
New +$51.8K ﹤0.01% 1394

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Summit Financial's TSHA Position: Q2 2026 in Review

Summit Financial reduced its Taysha Gene Therapies (TSHA) stake by 2.3% in Q2 2026, selling an estimated $1.54K and leaving 10,888 shares worth $74.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

Summit Financial first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Summit Financial held 10,888 shares of Taysha Gene Therapies worth $74.1K as of Q2 2026.
  • Summit Financial sold 260 Taysha Gene Therapies shares in Q2 2026, an estimated $1.54K.
  • Taysha Gene Therapies made up ﹤0.01% of Summit Financial's portfolio in Q2 2026, its #1567 holding.
  • Summit Financial first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.